Key Highlights
- Highlander Health acquires Target RWE, a leader in real-world evidence, to enhance clinical research and personalized care.
- Target RWE specializes in high-quality longitudinal data, supporting drug development and clinical strategies in the US and Europe.
- Highlander Health Partners, co-founded by Amy Abernethy, M.D., Ph.D., and Brad Hirsch, M.D., aims to modernize evidence generation for the medical innovation era.
- Acquisition marks Highlander Health’s first major investment, aligning with its mission to revolutionize patient care.
- Target RWE’s industry-standard data platform enables state-of-the-art research, filling evidence and quality gaps.
Source: Business Wire
Notable Quotes
- “Amy and I co-founded Highlander Health to solve big challenges in health care, and the acquisition of Target RWE is an important step in that endeavor. We are looking forward to working with Target RWE to dramatically improve clinical evidence generation.” — Brad Hirsch, M.D., Co-founder at Highlander Health
- “High quality longitudinal real-world data can and should form the foundation for better understanding which medical interventions work for which patients and when. Appropriately guided technology can improve the process, but only when science and ethics come first.” — Amy Abernethy, M.D., Ph.D., Co-founder at Highlander Health
- “The Target RWE team is excited for the next phase in our journey developing state-of-the-art clinical research evidence to support improved patient care. Amy and Brad’s extensive experience will help us build on our prior work and ultimately provide better care for more patients.” — Michael W. Fried, M.D., FAASLD, Chief Medical Officer at Target RWE
Why This Matters
This acquisition signifies a pivotal moment in healthcare innovation, leveraging Target RWE’s regulatory-grade datasets to address critical gaps in evidence and improve patient outcomes. By combining Target RWE’s capabilities with Highlander Health’s mission-driven leadership, the partnership is poised to set new standards in clinical research and personalized care. This move reflects a broader industry shift toward integrating real-world evidence into drug development and patient care strategies.
